Annotation Detail
Information
- Associated Genes
- ERBB2
- Associated Variants
-
ERBB2 AMPLIFICATION
(
ENST00000269571.10 )
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) - Associated Disease
- Her2-receptor positive breast cancer
- Source Database
- CIViC Evidence
- Description
- The Phase III trial, TH3RESA (NCT01419197), was performed in patients with advanced HER2 breast cancer that was heavily pretreated. Patients were required to have prior exposure to trastuzumab and lapatinib as well as a taxane. This patient population has not seen many studies, responds poorly to late-line treatment with trastuzumab, and in this study was treated with trastuzumab emtansine (T-DM1, n=404) vs. physician's choice (usually trastuzumab plus chemotherapy, n=198). Results showed progression free survival was 6.2 months in T-DM1 treatment vs. 3.3 months under physician's choice, along with lower incidence of grade 3 or worse events with T-DM1. The authors conclude that their findings in this heavily pretreated population, along with findings in the EMILIA trial, indicate promise for antibody-drug conjugates. The NCI-MATCH trial with further study T-DM1 in the context of HER2 amplification.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1159
- Gene URL
- https://civic.genome.wustl.edu/links/genes/20
- Variant URL
- https://civic.genome.wustl.edu/links/variants/306
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Her2-receptor Positive Breast Cancer
- Evidence Direction
- Supports
- Drug
- Trastuzumab Emtansine
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 24793816
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Trastuzumab Emtansine | Sensitivity | true |